RGEN Repligen Corporation

-0.77  -1%
Previous Close 85.95
Open 84.7
Price To Book 6.54
Market Cap 4,089,030,976
Shares 48,004,590
Volume 145,656
Short Ratio
Av. Daily Volume 496,765

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received June 22, 2012.
Detection of pancreatic duct abnormalities

Latest News

  1. Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes
  2. Repligen Corporation (NASDAQ:RGEN): Financial Strength Analysis
  3. Edited Transcript of RGEN earnings conference call or presentation 9-May-19 12:30pm GMT
  4. Here's Why Repligen Gained 62.9% in the First Half of 2019
  5. Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
  6. Here is Why Growth Investors Should Buy Repligen (RGEN) Now
  7. The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products
  8. U.S. Economy Likely to Sustain Longest Expansion: 5 Top Picks
  9. Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
  10. Inovio Up on Enrollment Closure in Cervical Dysplasia Study
  11. Pacira Gets EMA Acceptance for Pain Management Drug Exparel
  12. Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
  13. Repligen Corporation (RGEN) Shares March Higher, Can It Continue?
  14. Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
  15. Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
  16. Wall Street Foresees a Fed Rate Cut: Winners & Losers
  17. See what the IHS Markit Score report has to say about Repligen Corp.
  18. 7 Top-Rated Biotech Stocks to Invest In Today
  19. NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag